SCHEMBL29664484

SCHEMBL29664484

O=C(O)c1ccccoc2cccnc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
LMNA P02545 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
NAPRT Q6XQN6 1/20 0.47
P4HTM Q9NXG6 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DAGLA Q9Y4D2 7/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
ACMSD Q8TDX5 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
FAAH O00519 8/20 0.41
KDM5A P29375 1/20 0.41
JMJD1C Q15652 1/20 0.41
KDM3A Q9Y4C1 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664499 0.87 SMN1; SMN2 (0.42) KDM4ELMNAMEN1KMT2ADAGLA
SCHEMBL29664645 0.76 NPC1 (0.36) KDM4ELMNAMEN1KMT2AP4HTM
SCHEMBL30505600 0.72 KDM4E (1.00) KDM4ELMNAMEN1KMT2ANAPRT
SCHEMBL30381290 0.72 KDM4E (1.00) KDM4ELMNAMEN1KMT2ANAPRT
SCHEMBL125654 0.72 KDM4E (1.00) KDM4ELMNAMEN1KMT2ANAPRT
SCHEMBL29664625 0.71 KDM4E (0.37) KDM4EMEN1KMT2ADAGLATSHR
Fluoride SCHEMBL28821496 0.70 KDM4E (0.96) KDM4ELMNAMEN1KMT2ANAPRT
Hydrochloric Acid SCHEMBL5266713 0.70 KDM4E (0.96) KDM4ELMNAMEN1KMT2ANAPRT
2-Picolinic Acid SCHEMBL12537807 0.68 LMNA (0.95) KDM4ELMNAKMT2ANAPRTP4HTM
2-Picolinic Acid SCHEMBL12537810 0.68 LMNA (0.95) KDM4ELMNAKMT2ANAPRTP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238296-A1 METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS FULCRUM THERAPEUTICS INC (US) 2024-07-18 US disclosed
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2023-02-28 US disclosed
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238296-A1 METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS BCLAF1, EED, BCL3 KDM4E 410/4885LMNA 2653/4885MEN1 3343/4885
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS EED, EZH2, BMI1 KDM4E 88/4885LMNA 2964/4885MEN1 1192/4885
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators EED, EZH2, BMI1 KDM4E 88/4885LMNA 2964/4885MEN1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.